Analysis of Financial Track Record
Value Creation |
|---|
| Dec'10 | Dec'11 | Dec'12 | Mar'14 | Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Capital Employed | 4.68% | 5.61% | 8.53% | 21.65% | 9.19% | 6.55% | 2.06% | 21.86% | 3.99% | 4.11% |
| Growth Parameters |
|---|
| 9 yrs | 5 yrs | 3 yrs | 1 yr | |
|---|---|---|---|---|
| Net Sales | 14.3% | 12.5% | 6.6% | 8.9% |
| Adjusted EPS | 7.6% | -12.9% | 35.6% | 0.9% |
| Book Value per Share | 4.3 | 7.4 | -0.6 | -2.5 |
| Share Price | 9.7% | -3.2% | 3.7% | 130.2% |
| Key Financial Parameter |
|---|
Management X-Ray
Shareholding Pattern
| Entity | Percentage Holding |
|---|---|
| Promoters | 29.69% |
| Institutions | 42.24% |
| Non-Institutions | 28.07% |
Promoter's Holding & Share Pledging
| Pledged * | 23.54 | 19.63 | 28.91 | 16.31 | 13.02 | 51.29 | 48.20 | 50.93 | 46.84 | 37.04 |
FAQs
MoneyWorks4Me analysed the past 10-year performance of Strides Pharma Science Ltd and arrived at the following conclusion:
Past 10 year's financial track record indicates that Strides Pharma Science Ltd is a below average quality company. However, for specific investment actions please connect with your investment advisor.The 5-year analysis of Strides Pharma Science Ltd's performance infers:
Strides Pharma Science Ltd earnings have declined by -12.9%, whereas share price has depreciated -3.2% CAGR over the past five years, indicating the company's share price is likely overvalued. However, for specific investment actions please connect with your investment advisor.We analysed the performance of Strides Pharma Science Ltd share prices over the last 10 years. Here is what we found out:
Strides Pharma Science Ltd share price has depreciated 8.1% annually over the past ten years. About Company
Strides Arcolab, incorporated in 1990, is engaged in the manufacture of pharmaceutical dosage forms in branded as well generic categories. The dosages are manufactured in form of tablets, capsules, soft gelatin capsules, parenterals and semi-solids.
The company manufactures soft gels and steriles. It has 13 manufacturing facilities located across the world -- in
Strides Arcolab, incorporated in 1990, is engaged in the manufacture of pharmaceutical dosage forms in branded as well generic categories. The dosages are manufactured in form of tablets, capsules, soft gelatin capsules, parenterals and semi-solids.
The company manufactures soft gels and steriles. It has 13 manufacturing facilities located across the world -- in
These facilities have received approval from various regulatory authorities namely MHHRA, TGA, MCC, ANVISA. The company’s
The company is among the top 5 soft gelatin capsule manufacturers in world.
Strides Acrolab has partnered with major pharmaceutical companies located in
The company has a joint venture with Akorn -- Akorn-Strides, LLC -- to develop liquid, lyophilized and dry powder formulations of generic injectable products targeting several therapeutic markets.
Products
Soft gel capsules- The company manufactures range of soft gel in category of nutraceuticals, Rx, specialty OTCs and immunosuppressants.
Steriles- Under this, it offers its products in therapeutic segments that includes beta-lactams and cephalosporins. The company manufactures striles in various forms such as prefill syringes, ampoules, vials and penicillins.
Outlook
Akorn-Strides, LLC has received approval from the US Food and Drug Administration for two Abbreviated New Drug Applications (ANDAs) for Sterile Vancomycin HCl USP, 500 mg/vial, 1 g/vial and Sterile Vancomycin HCl USP, 5 g/vial Pharmacy Bulk Package.
